266 related articles for article (PubMed ID: 35515123)
1. Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.
Shu Y; Ding Y; Zhang Q
Front Oncol; 2022; 12():851522. PubMed ID: 35515123
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Jiang Y; Li Y; Wang LXW
Int J Clin Pharm; 2022 Apr; 44(2):499-506. PubMed ID: 35088231
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis.
Zhang PF; Shi XQ; Li Q
Cost Eff Resour Alloc; 2023 Sep; 21(1):65. PubMed ID: 37705023
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.
Shu Y; Ding Y; Li F; Zhang Q
Int Immunopharmacol; 2023 Jan; 114():109589. PubMed ID: 36700770
[TBL] [Abstract][Full Text] [Related]
5. First-line nivolumab plus chemotherapy
Cao X; Zhang M; Li N; Zheng B; Liu M; Song X; Cai H
Ther Adv Med Oncol; 2023; 15():17588359231171038. PubMed ID: 37223263
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan.
Morimoto K; Moriwaki K; Shimozuma K; Nakayama T
J Gastroenterol; 2023 Dec; 58(12):1188-1197. PubMed ID: 37725256
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma.
Liu S; Dou L; Wang K; Shi Z; Wang R; Zhu X; Song Z; Li S
Front Oncol; 2022; 12():899966. PubMed ID: 35936686
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer.
Wan X; Zeng X; Peng L; Peng Y; Liu Q; Yi L; Luo X; Deng Q; Tan C
Front Pharmacol; 2021; 12():580459. PubMed ID: 34512315
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer.
Hao X; Shen A; Wu B
Front Pharmacol; 2021; 12():573852. PubMed ID: 34290602
[No Abstract] [Full Text] [Related]
11. First-line nivolumab plus ipilimumab or chemotherapy
Cao X; Cai H; Li N; Zheng B; Zheng Z; Liu M
Ther Adv Med Oncol; 2022; 14():17588359221122733. PubMed ID: 36147862
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer.
Hu H; She L; Liao M; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Carbone DP; Huang J
Front Oncol; 2020; 10():1649. PubMed ID: 33014826
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
14. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Liu T; Bai Y; Lin X; Li W; Wang J; Zhang X; Pan H; Bai C; Bai L; Cheng Y; Zhang J; Zhong H; Ba Y; Hu W; Xu R; Guo W; Qin S; Yang N; Lu J; Shitara K; Lei M; Li M; Bao N; Chen T; Shen L
Int J Cancer; 2023 Feb; 152(4):749-760. PubMed ID: 36121651
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.
Ye ZM; Tang ZQ; Xu Z; Zhou Q; Li H
Front Public Health; 2022; 10():947375. PubMed ID: 35937220
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective.
Marupuru S; Arku D; Axon DR; Villa-Zapata L; Yaghoubi M; Slack MK; Warholak T
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):831-841. PubMed ID: 37243493
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China.
Li S; Peng L; Tan C; Zeng X; Wan X; Luo X; Yi L; Li J
PLoS One; 2020; 15(5):e0232240. PubMed ID: 32379763
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.
Huang Y; You M; Wu Q; Chen R
Front Pharmacol; 2023; 14():1238009. PubMed ID: 37719841
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
Shu Y; Tang Y; Ding Y; Zhang Q
Int Immunopharmacol; 2023 Sep; 122():110543. PubMed ID: 37406395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
